InMed Pharmaceuticals Inc.: Fairmount Funds Management LLC discloses a stake of more than 5% (Schedule 13D)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Fairmount Funds Management LLC disclosed a stake exceeding 5% in InMed Pharmaceuticals Inc. via a Schedule 13D filing with the SEC (accession 0001193125-26-458677). The 13D designation signals active intent rather than passive ownership, though the filing summary did not specify the exact share count or percentage held. The move puts Fairmount among InMed's significant holders and may give it influence over corporate decisions at the clinical-stage cannabinoid drug developer. Investors will watch for amendments disclosing the purpose of the stake, any board or strategy discussions, and whether Fairmount pushes for changes at the company.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Fairmount Funds Management LLC, InMed Pharmaceuticals Inc.